We believe 2017 is going to be a year of contrasting performance with the first half being more challenging, driven by domestic and global events and the second half seeing a sharp recovery.
From the look of it 2017 is unlikely to be any easier. Pricing pressures in USâ€“ the world‘s largest market for generic drugsâ€”tighter regulatory scrutiny by the US FDA and thereby higher compliance costs, global macro-economic uncertainty and price controls back home are expected to continue in the 2017.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.